Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
treatment group:combination of Lopinavir/ritonavir (Kaletra) Tablets and interferon
control group:Routine medical treatment,
Sponsors
Diagnosis, treatment and Research Center for infectious diseases, the fifth medical center of the PLA
Eligibility
Sex/Gender
All
Age
16 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. patients aged 16-85 male or female; 2. they were willing to sign the informed consent; 3. The novel coronavirus nucleic acid was detected by real-time fluorescence RT-PCR in sputum, throat swabs, and lower respiratory tract secretions based on the novel coronavirus infection suspected case standard; Sequencing of viral genes is highly homologous to Known novel coronavirus.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. patients with malignant tumor, other serious systemic diseases and psychosis; 3. patients with severe liver dysfunction; 4. recent or participating in other clinical trials; 5. evidence of drug addiction within one year before joining the trial; 6. unable or unwilling to provide informed consent or comply with the trial requirements; 7. Combined with other infectious diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time till the SARS-CoV-2 clearance; | — |
Secondary
| Measure | Time frame |
|---|---|
| novel coronavirus nucleic acid clearance rate; | — |
Countries
China
Contacts
Public ContactZhe Xu
Diagnosis, treatment and Research Center for infectious diseases, the fifth medical center of the PLA
Outcome results
None listed